Your Health, We Care
Fidaxomicin is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Fidaxomicin and other antibacterial drugs, Fidaxomicin should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
FDA,2020.05
Fidaxomicin is an innovative drug carefully developed by Optimer, specially desi···【more】
Release date：2024-08-29Recommended：129
Fidaxomicin is an antibiotic developed by Optimer, which targets the unique mech···【more】
Release date：2024-08-29Recommended：121
Fidaxomicin is an innovative macrolide antibiotic developed by Optimer, which is···【more】
Release date：2024-08-29Recommended：111
Clostridium difficile, a prevalent enteric pathogen, is known to induce profound···【more】
Release date：2024-08-05Recommended：115
Fidaxomicin, a macrolide antibiotic sanctioned by the US FDA in 2011, boasts a d···【more】
Release date：2024-08-05Recommended：129
Fidaxomicin, a potent antibiotic medication, serves as a pivotal remedy for the ···【more】
Release date：2024-08-05Recommended：147
